NYSEAMERICAN:TRXC - TransEnterix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.76 0.00 (0.00 %)
(As of 02/19/2019 04:00 PM ET)
Previous Close$2.76
Today's Range$2.67 - $2.79
52-Week Range$1.39 - $6.98
Volume1.86 million shs
Average Volume2.25 million shs
Market Capitalization$596.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$596.49 million
OptionableOptionable

TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its earnings results on Tuesday, August, 7th. The medical instruments supplier reported ($0.06) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.06). The medical instruments supplier had revenue of $6.39 million for the quarter, compared to the consensus estimate of $6.20 million. View TransEnterix's Earnings History.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for TransEnterix.

What guidance has TransEnterix issued on next quarter's earnings?

TransEnterix updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $24-24 million, compared to the consensus revenue estimate of $23.89 million.TransEnterix also updated its Q4 2018 guidance to EPS.

What price target have analysts set for TRXC?

3 brokerages have issued 12-month target prices for TransEnterix's shares. Their forecasts range from $5.00 to $5.50. On average, they expect TransEnterix's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 90.2% from the stock's current price. View Analyst Price Targets for TransEnterix.

What is the consensus analysts' recommendation for TransEnterix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.

What are Wall Street analysts saying about TransEnterix stock?

Here are some recent quotes from research analysts about TransEnterix stock:
  • 1. According to Zacks Investment Research, "TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. " (1/11/2019)
  • 2. BTIG Research analysts commented, "with TransEnterix announced the acquisition of MST Israeli company that has created an image analytics technology that uses artificial intelligence, scene recognition, and machine learning. With the cash + stock transaction (worth ~$33M as of 9/21 closing price) expected to close in Q4, TRXC will pick up the IP portfolio (30 patents, 31 pending), technology assets, and MST’s employees. Though the co’s AutoLap platform has FDA 510(k) and CE Mark clearance, TRXC does not intend to sell it as a standalone product. Instead, its capabilities— including dynamic 3D digital measurement, auto zoom, and anatomical structure identification—will be integrated into Senhance. Timing for these enhancements is unclear, though it is likely to take quarters, not years. We see this as an exciting step toward advanced digital laparoscopy, but our near-term focus remains on system sales." (9/25/2018)

Has TransEnterix been receiving favorable news coverage?

Press coverage about TRXC stock has been trending neutral on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransEnterix earned a news impact score of 0.4 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.

Are investors shorting TransEnterix?

TransEnterix saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 36,343,750 shares, a drop of 2.1% from the January 15th total of 37,107,265 shares. Based on an average daily volume of 1,781,222 shares, the days-to-cover ratio is currently 20.4 days. Currently, 20.4% of the shares of the stock are short sold. View TransEnterix's Current Options Chain.

Who are some of TransEnterix's key competitors?

Who are TransEnterix's key executives?

TransEnterix's management team includes the folowing people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.35%), Mirae Asset Global Investments Co. Ltd. (2.02%), Northern Trust Corp (0.91%), Geode Capital Management LLC (0.84%), Masters Capital Management LLC (0.81%) and First Trust Advisors LP (0.48%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, Todd Pope, Willam N Kelley and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.

Which institutional investors are selling TransEnterix stock?

TRXC stock was sold by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., Eagle Asset Management Inc., California Public Employees Retirement System, Barclays PLC, MetLife Investment Advisors LLC, Jane Street Group LLC, New York State Common Retirement Fund and Two Sigma Advisers LP. Company insiders that have sold TransEnterix company stock in the last year include Anthony C J Fernando, Joseph P Slattery, Todd Pope and William N Starling Jr. View Insider Buying and Selling for TransEnterix.

Which institutional investors are buying TransEnterix stock?

TRXC stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Masters Capital Management LLC, Bank of New York Mellon Corp, Geode Capital Management LLC, HRT Financial LLC, Rhumbline Advisers and Alps Advisors Inc.. Company insiders that have bought TransEnterix stock in the last two years include Richard C Pfenniger Jr and Willam N Kelley. View Insider Buying and Selling for TransEnterix.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $2.76.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $596.49 million.

What is TransEnterix's official website?

The official website for TransEnterix is http://www.transenterix.com.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.


MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  332 (Vote Underperform)
Total Votes:  626
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Featured Article: What is the Current Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel